Study Programmes 2015-2016
Advanced Master in Industrial Pharmacy
| Cycle view of the study programme | Bl | Or | Th | Pr | Ot | Cr | |||||||||||||||
| Information | |||||||||||||||||||||
| Professor Ph. HUBERT Analytical Chemistry Laboratory Building B36 - CHU - 4000 Liège Phone : 04/366.43.16 - Fax : 04/366.43.17 e-mail address : Ph.Hubert@ulg.ac.be |
|||||||||||||||||||||
| Collegiality | |||||||||||||||||||||
| Coordinator : Philippe HUBERT ULg : Vincent BIERLAIRE, Bruno BOULANGER, Raphaël DENOOZ, Dominique MARTIN, Laurence DENIS, Brigitte EVRARD, Marianne FILLET, Bernard PIROTTE, Eric ROZET, André SCHEEN, Monique TITS, Jean-Michel VANDERHOFSTADT, Eric ZIEMONS. ULB : Karim AMIGHI, Sonja BEKEN, Daniel BRASSEUR, Jean-Antoine DE MUYLDER, Patrick DI STEFANO, Pierre DUEZ, François DUFRASNES, Véronique FONTAINE, Ghanem GHANEM, Jean-Michel KAUFFMAN, A. LENAERS, Pierre VAN ANTWERPEN, Francis VANDERBIST, David VERMIJLEN. Pour l'UCL : Catherine DRUEZ, Bernadette GOVAERTS, Philippe LEVEQUE, Xavier MARCELIS, Jacques POUPAERT, Joëlle QUETIN-LECLERCQ, Nevin SERBEST, Jean SCOUVART, Rita VAN BEVER, Roger VERBEECK, N... |
|||||||||||||||||||||
| Study programme | |||||||||||||||||||||
| Compulsory courses (B1 : 60Cr) | |||||||||||||||||||||
| Active substances | B1 | Q1 | 6 | ||||||||||||||||||
| Active substances | |||||||||||||||||||||
| - | Substances issues de recherches pharmacochimiques, part a - Bernard Pirotte | 10 | - | - | |||||||||||||||||
| Substances issues de recherches pharmacochimiques, part a - Bernard Pirotte | |||||||||||||||||||||
| - | Substances issues de recherches pharmacochimiques, part b - Françoise Dufrasne | 5 | - | - | |||||||||||||||||
| Substances issues de recherches pharmacochimiques, part b - Françoise Dufrasne | |||||||||||||||||||||
| - | Substances issues des biotechnologies - David Vermijlen | 15 | - | - | |||||||||||||||||
| Substances issues des biotechnologies - David Vermijlen | |||||||||||||||||||||
| - | Substances d'origine naturelle, part a - Joëlle Quetin-Leclercq | 5 | - | - | |||||||||||||||||
| Substances d'origine naturelle, part a - Joëlle Quetin-Leclercq | |||||||||||||||||||||
| - | Substances d'origine naturelle, part b - Pierre Duez | 5 | - | - | |||||||||||||||||
| Substances d'origine naturelle, part b - Pierre Duez | |||||||||||||||||||||
| - | Produits radiopharmaceutiques - Ghanem Ghanem | 10 | - | - | |||||||||||||||||
| Produits radiopharmaceutiques - Ghanem Ghanem | |||||||||||||||||||||
| Clinical viewpoints | B1 | 6 | |||||||||||||||||||
| Clinical viewpoints | |||||||||||||||||||||
| - | Métabolisme des médicaments et paramètres pharmacocinétiques - Roger Verbeek | 20 | - | - | |||||||||||||||||
| Métabolisme des médicaments et paramètres pharmacocinétiques - Roger Verbeek | |||||||||||||||||||||
| - | Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - Régis Radermecker | 15 | - | - | |||||||||||||||||
| Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - Régis Radermecker | |||||||||||||||||||||
| - | Information et pharmacovigilance - Raphaël Denooz | 10 | - | - | |||||||||||||||||
| Information et pharmacovigilance - Raphaël Denooz | |||||||||||||||||||||
| Quality assurance and pharmaceutical management | B1 | 7 | |||||||||||||||||||
| Quality assurance and pharmaceutical management | |||||||||||||||||||||
| - | Principles of pharmaceutical management - Jean-Michel Van Der Hofstadt | 10 | - | - | |||||||||||||||||
| Principles of pharmaceutical management - Jean-Michel Van Der Hofstadt | |||||||||||||||||||||
| - | Quality assurance, part a : basic concepts and quality assurance organisation - Jean Scouvart | 20 | - | - | |||||||||||||||||
| Quality assurance, part a : basic concepts and quality assurance organisation - Jean Scouvart | |||||||||||||||||||||
| - | Quality assurance, part b : Analytical technology of procedures and risk analysis - Xavier Marcelis | 7,5 | - | - | |||||||||||||||||
| Quality assurance, part b : Analytical technology of procedures and risk analysis - Xavier Marcelis | |||||||||||||||||||||
| - | English applied to the pharmaceutical industry - Jacques Poupaert, Nevin Serbest | 20 | - | - | |||||||||||||||||
| English applied to the pharmaceutical industry - Jacques Poupaert, Nevin Serbest | |||||||||||||||||||||
| - | Pharmaceutical marketing - Vincent Bierlaire | 7,5 | - | - | |||||||||||||||||
| Pharmaceutical marketing - Vincent Bierlaire | |||||||||||||||||||||
| Industrial pharmaceutical technology | B1 | 8 | |||||||||||||||||||
| Industrial pharmaceutical technology | |||||||||||||||||||||
| - | Industrial pharmaceutical microbiology - Véronique Fontaine | 15 | - | - | |||||||||||||||||
| Industrial pharmaceutical microbiology - Véronique Fontaine | |||||||||||||||||||||
| - | Preformulation and selection of galenical forms - Karim Amighi | 15 | - | - | |||||||||||||||||
| Preformulation and selection of galenical forms - Karim Amighi | |||||||||||||||||||||
| - | Industrial production of galenical forms - Brigitte Evrard | 15 | - | - | |||||||||||||||||
| Industrial production of galenical forms - Brigitte Evrard | |||||||||||||||||||||
| - | Industrial production of biomolecules - Philippe Leveque, Rita Van Bever | 15 | - | - | |||||||||||||||||
| Industrial production of biomolecules - Philippe Leveque, Rita Van Bever | |||||||||||||||||||||
| - | Industrial aspects of technological development including packaging - Laurence Denis | 10 | - | - | |||||||||||||||||
| Industrial aspects of technological development including packaging - Laurence Denis | |||||||||||||||||||||
| Drug analysis | B1 | 7 | |||||||||||||||||||
| Drug analysis | |||||||||||||||||||||
| - | Analytical methods and pharmaceutical and biopharmaceutical control, part a - Jean-Michel Kauffman, Pierre Van Antwerpen | 10 | - | - | |||||||||||||||||
| Analytical methods and pharmaceutical and biopharmaceutical control, part a - Jean-Michel Kauffman, Pierre Van Antwerpen | |||||||||||||||||||||
| - | Analytical methods and pharmaceutical and biopharmaceutical control, part b - Marianne Fillet | 10 | - | - | |||||||||||||||||
| Analytical methods and pharmaceutical and biopharmaceutical control, part b - Marianne Fillet | |||||||||||||||||||||
| - | Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment - Philippe Hubert, Roland Marini Djang'Eing'A | 15 | - | - | |||||||||||||||||
| Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment - Philippe Hubert, Roland Marini Djang'Eing'A | |||||||||||||||||||||
| - | Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology - Philippe Hubert, Eric Ziemons | 5 | - | - | |||||||||||||||||
| Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology - Philippe Hubert, Eric Ziemons | |||||||||||||||||||||
| - | Statistical methods applied to the pharmaceutical industry - Bernadette Govaerts | 15 | - | - | |||||||||||||||||
| Statistical methods applied to the pharmaceutical industry - Bernadette Govaerts | |||||||||||||||||||||
| - | Experimental planning and "quality by design" - Bruno Boulanger | 10 | - | - | |||||||||||||||||
| Experimental planning and "quality by design" - Bruno Boulanger | |||||||||||||||||||||
| Regulation and the medical-social environment | B1 | 8 | |||||||||||||||||||
| Regulation and the medical-social environment | |||||||||||||||||||||
| - | Economic aspects of drug development - Dominique Martin | 10 | - | - | |||||||||||||||||
| Economic aspects of drug development - Dominique Martin | |||||||||||||||||||||
| - | Legislation and procedures applied to pharmaceutical industry, part a : legislation - Catherine Druez | 10 | 5 | - | |||||||||||||||||
| Legislation and procedures applied to pharmaceutical industry, part a : legislation - Catherine Druez | |||||||||||||||||||||
| - | Legislation and procedures applied to pharmaceutical industry, part b : patents and protection - Patrick Di Stefano | 5 | - | - | |||||||||||||||||
| Legislation and procedures applied to pharmaceutical industry, part b : patents and protection - Patrick Di Stefano | |||||||||||||||||||||
| - | Macroeconomic environment and pharmaco-economics - Pierre Duez | 10 | - | - | |||||||||||||||||
| Macroeconomic environment and pharmaco-economics - Pierre Duez | |||||||||||||||||||||
| - | CTD File (Common Technical Document) - Jean-Antoine De Muylder | 15 | - | - | |||||||||||||||||
| CTD File (Common Technical Document) - Jean-Antoine De Muylder | |||||||||||||||||||||
| - | Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files - Sonia Beken | 15 | - | - | |||||||||||||||||
| Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files - Sonia Beken | |||||||||||||||||||||
| - | Regulations of preclinical and clinical studies, part b : clinical studies - A Lenaers | 5 | - | - | |||||||||||||||||
| Regulations of preclinical and clinical studies, part b : clinical studies - A Lenaers | |||||||||||||||||||||
| - | Regulations of preclinical and clinical studies, part c : pediatric studies - Daniel Brasseur | 2,5 | - | - | |||||||||||||||||
| Regulations of preclinical and clinical studies, part c : pediatric studies - Daniel Brasseur | |||||||||||||||||||||
| - | Specific regulatory issues, part a : medicine and herbal dietary supplement - Michel Frederich | 5 | - | - | |||||||||||||||||
| Specific regulatory issues, part a : medicine and herbal dietary supplement - Michel Frederich | |||||||||||||||||||||
| - | Specific regulatory issues, part b : Preformulation and galenical development documentation - Francis Vanderbist | 5 | - | - | |||||||||||||||||
| Specific regulatory issues, part b : Preformulation and galenical development documentation - Francis Vanderbist | |||||||||||||||||||||
| Visits and seminars organised in the pharmaceutical industry - Françoise Dufrasne, Brigitte Evrard, Rita Van Bever - [77,5h Vis.] | B1 | - | - | [+] | 3 | ||||||||||||||||
| Visits and seminars organised in the pharmaceutical industry - Françoise Dufrasne, Brigitte Evrard, Rita Van Bever - [77,5h Vis.] | |||||||||||||||||||||
| Final work - Françoise Dufrasne, Brigitte Evrard, Rita Van Bever | B1 | - | - | - | 15 | ||||||||||||||||
| Final work - Françoise Dufrasne, Brigitte Evrard, Rita Van Bever | |||||||||||||||||||||